CAMP

Camp 4 Therapeutics Stock Analysis

AI Rating

Low
  • Quality6/10
  • Growth↓ 3/10
  • Value↓ 0/10
Camp 4 Therapeutics sales and earnings growth
CAMP Growth
Neutral
  • Revenue Y/Y↑ 436.50%
  • EPS Y/Y↑ 76.00%
  • FCF Y/Y↑ 35.23%
Camp 4 Therapeutics gross and profit margin trends
CAMP Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -2298.50%
  • ROIC 5Y↓ 0.00%
Camp 4 Therapeutics net debt vs free cash flow
CAMP Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Camp 4 Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗